|
Aug 7
|
Astria Therapeutics licenses navenibart rights to Kaken for HAE
|
|
Aug 6
|
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
|
|
Jun 13
|
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
|
|
May 13
|
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
|
|
Mar 11
|
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
|
|
Feb 27
|
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
|
|
Feb 25
|
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
|
|
Feb 22
|
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)
|
|
Feb 20
|
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
|
|
Oct 30
|
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
|
|
Sep 30
|
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
|
|
Sep 27
|
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
|
|
May 11
|
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
|
|
May 9
|
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
May 8
|
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
|
|
Apr 9
|
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
|
|
Apr 3
|
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
|
|
Mar 25
|
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
|
|
Mar 23
|
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
|
|
Mar 4
|
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
|